Rochester, NY 7/14/2009 2:29:12 AM
WhisperfromWallStreet.com Stock Report - PLX - Protalix Initiates a Home Care Treatment Program for Gaucher Patients in the Phase III Extension Trial of prGCD
Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc., PLX
Protalix BioTherapeutics, Inc., announced today the initiation of a home care treatment program for patients enrolled in the Company’s phase III extension trial of plant-cell expressed recombinant glucocerebrosidase (prGCD), the Company’s lead product candidate. The phase III extension trial is a follow-on study to the Company’s on-going pivotal phase III clinical trial, which is evaluating the safety and efficacy of prGCD in treatment-naive patients of Gaucher disease, a lysosomal storage disorder in humans.
ABOUT THE COMPANY
Philip Morris International Inc manufactures and sells cigarettes and other tobacco products in markets outside of the United States of America. The companys portfolio comprises international and local brands.
5.01 Up 0.16 (3.30%) 3:14pm ET
Last Trade: 5.01
Day's Range: 4.90 - 5.05
52wk Range: N/A
Volume: 184,111
There are hundreds of stocks that rise and fall each day, our expertise is understanding which have the best opportunity for rapid growth. Our newsletter has sent out over 40 alerts this year with an average price gain of 80%. If you like to be alerted to the stocks that meets our criteria. Please join us for free to track our results.
You can sign up now for free stock alerts at WhisperfromWallStreet.com
Please read the COMPLETE DISCLAIMER posted on our website.
IMPORTANT NOTE: This is not a solicitation to buy or sell any securities. Neither WhisperfromWallStreet.com, nor any of its affiliates are registered investment advisors or a broker dealer. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.
